SRR23036889
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.450
- G2M_CHECKPOINT+0.400
- MYC_TARGETS_V1+0.390
- WNT_BETA_CATENIN_SIGNALING+0.350
- MYC_TARGETS_V2+0.320
- OXIDATIVE_PHOSPHORYLATION+0.240
- DNA_REPAIR+0.210
- ANGIOGENESIS+0.190
- ADIPOGENESIS+0.100
- P53_PATHWAY+0.100
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.380
- INTERFERON_GAMMA_RESPONSE-0.360
- TNFA_SIGNALING_VIA_NFKB-0.340
- COMPLEMENT-0.320
- COAGULATION-0.310
- IL6_JAK_STAT3_SIGNALING-0.310
- HYPOXIA-0.270
- IL2_STAT5_SIGNALING-0.260
- INFLAMMATORY_RESPONSE-0.250
- MYOGENESIS-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_K25F4J3V | ATRT | — | 0.850 |
| 2 | TCGA-77-8154-01A-11R-2247-07 | — | cohortSQ1 | 0.844 |
| 3 | TCGA-NC-A5HH-01A-11R-A26W-07 | — | cohortMD1 | 0.844 |
| 4 | C3L-01285 | — | cohortSQ2 | 0.843 |
| 5 | 176e93be-1ae5-43f2-a0b5-17f31695e679 | — | — | 0.839 |
| 6 | 1b572d35-f98e-4389-b234-a2591a74d7a8 | — | — | 0.839 |
| 7 | MNG164 | — | — | 0.837 |
| 8 | TCGA-55-7570-01A-11R-2039-07 | — | cohortA3 | 0.836 |
| 9 | MNG392 | — | — | 0.831 |
| 10 | 2b17db8f-c184-498d-9a10-c6d8a5061206 | — | — | 0.828 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.450 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.390 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.350 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.320 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.240 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.210 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.190 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.100 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.080 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.080 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.040 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.030 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.020 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.010 | Inavolisib | — uncovered |
| PEROXISOME | 0.010 | Idelalisib | — uncovered |